Development of a human model for the study of effects of hypoxia, exercise, and sildenafil on cardiac and vascular function in chronic heart failure by Clark, Andrew L.. et al.
ORIGINAL ARTICLE
Development of a Human Model for the Study of Effects
of Hypoxia, Exercise, and Sildenafil on Cardiac and
Vascular Function in Chronic Heart Failure
Thibaud Damy, MD, PhD,*†‡§ James Hobkirk, PhD,* Mandy Walters,* Andrea Ciobanu, MD,*
Alan S. Rigby, PhD,* Anna Kallvikbacka-Bennett,* Aziz Guellich, PhD,†§
Jean-Luc Dubois-Randé, MD, PhD,†‡§ Luc Hittinger, MD, PhD,†‡§ Andrew L. Clark, MA, MD, FRCP,*
and John G. F. Cleland, MD, FACC*¶
Background: Pulmonary hypertension is associated with poor
outcome in patients with chronic heart failure (CHF) and may be
a therapeutic target. Our aims were to develop a noninvasive
model for studying pulmonary vasoreactivity in CHF and
characterize sildenaﬁl’s acute cardiovascular effects.
Methods and Results: In a crossover study, 18 patients with
CHF participated 4 times [sildenaﬁl (2 · 20 mg)/or placebo
(double-blind) while breathing air or 15% oxygen] at rest
and during exercise. Oxygen saturation (SaO2) and systemic
vascular resistance were recorded. Left and right ventricular
(RV) function and transtricuspid systolic pressure gradient
(RVTG) were measured echocardiographically. At rest,
hypoxia caused SaO2 (P = 0.001) to fall and RVTG to rise
(5 6 4 mm Hg; P = 0.001). Sildenaﬁl reduced SaO2 (21 6
2%; P = 0.043), systemic vascular resistance (287 6 156
dyn$s21$cm22; P = 0.034), and RVTG (22 6 5 mm Hg; P =
0.05). Exercise caused cardiac output (2.1 6 1.8 L/min; P ,
0.001) and RVTG (19 6 11 mm Hg; P , 0.0001) to rise. The
reduction in RVTG with sildenaﬁl was not attenuated by hyp-
oxia. The rise in RVTG with exercise was not substantially
reduced by sildenaﬁl.
Conclusions: Sildenaﬁl reduces SaO2 at rest while breathing
air, this was not exacerbated by hypoxia, suggesting increased
ventilation–perfusion mismatching due to pulmonary vasodila-
tion in poorly ventilated lung regions. Sildenaﬁl reduces RVTG
at rest and prevents increases caused by hypoxia but not by
exercise. This study shows the usefulness of this model to eval-
uate new therapeutics in pulmonary hypertension.
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sildenaﬁl, noninvasive hemodynamics, echocardiography
(J Cardiovasc Pharmacol 2015;66:229–238)
INTRODUCTION
Chronic heart failure (CHF) is common, and treatment
remains imperfect. New therapeutic targets and strategies
should be sought. The Euro Heart Failure survey reported that
16% of an epidemiologically representative population of
patients with CHF had pulmonary hypertension (PH).1 Large
retrospective studies suggest that the prevalence of PH in
CHF is high and describe PH as a strong predictor of an
adverse prognosis.2,3
In healthy subjects, the pulmonary circulation responds
to acute hypoxia with arteriolar vasoconstriction and a rise in
pulmonary artery (PA) pressure4–8 and to moderate exercise
with pulmonary vasodilatation that accommodates the rise in
cardiac output (CO) that prevents a rise in PA pressure.9 In
CHF, increases in both pulmonary arteriolar tone and left
atrial pressure may contribute to the development of PH.
Hypertrophy of pulmonary arterioles10 may result in persis-
tent PH that might progress autonomously. The increase in
right ventricular (RV) afterload caused by PH may be an
important determinant of RV dysfunction.11 Accordingly,
PH might be an appropriate target for treatment in patients
with CHF.
The aims of this study were to develop a model to
assess the cardiovascular effects of drugs on PA pressure at
rest, and during hypoxia and exercise, 2 interventions that are
known to increase PA pressure in patients with CHF12,13 and
to use it to assess the effects of sildenaﬁl, a possible treatment
for PH in patients with CHF.14
METHODS
Study Population
Patients were recruited from the Heart Failure clinic at
Castle Hill Hospital. Inclusion criteria were stable heart failure
and either left ventricular (LV) ejection fraction (LVEF),40%
or aminoterminal probrain natriuretic peptide (NT-pro-BNP)
$50 pmol/L (423 pg/mL) and mild-to-moderate tricuspid
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regurgitation on Doppler echocardiography. Patients with
arrhythmia (including atrial ﬁbrillation), severe tricuspid regur-
gitation, primary valve disease, severe optic neuropathy, oxy-
gen saturation (SaO2) on air at rest ,90%, SBP .170/110
mm Hg or unstable angina were excluded. Written informed
consent and local ethical approval were obtained.
Study Design, Drugs, and Gas Administration
The study was a double-blind crossover trial conducted
on 4 separate days. Patients were asked to breath air or 15%
oxygen (single-blind) for 2 hours before receiving 2 oral doses,
30 minutes apart, of either placebo or sildenaﬁl 20 mg (Pﬁzer,
Sandwich, United Kingdom) in a double-blind fashion. This
dosing regimen was designed to minimize the risk of
hypotension and to enhance the chance of a steady-state drug
concentration during the period of study. The hypoxic gas was
a mixture of 15% oxygen balanced with nitrogen (BOC Gases,
United Kingdom). Patients inhaled air or gas through a 2-way
no-rebreathe valve and a tightly ﬁtting face mask (Hans
Rudolph) attached through rubber tubing to a Douglas bag
(Cranlea, United Kingdom) if breathing hypoxic gas mixture or
open to room air. The order of treatment was allocated using
computer-generated random number blocks using a block size
of 2.15–18 The minimum wash-out duration between any 2 of
the 4 test days was 48 hours.
Study Protocol
At the initial screening visit, demographic data, medical
history, and treatment were recorded, and a full physical
examination was performed. Patients were asked to continue
their usual daily treatment without interruption. On each
study day, the patient rated his or her general experience of
breathlessness in the previous 24 hours on a 10-point scale to
detect symptom instability between study days.19
On each study day (Fig. 1), patients were ﬁrst studied at
rest after breathing air for 30 minutes. Systemic hemodynam-
ics, including systolic blood pressure (SBP), diastolic blood
pressure, heart rate (HR), systemic vascular resistance (SVR),
stroke volume, and CO were measured noninvasively and
continuously using ﬁnger volume-clamp technology (Nexﬁn,
BMEYE B.V. Netherlands). Oxygen saturation was measured
continuously using a transcutaneous oximeter (Avant 4000;
Nonin Medical Inc), and the mean value was calculated dur-
ing 2 minutes at each preplanned time (75 minutes rest, exer-
cise, and recovery). A brief echocardiogram was performed
(Echo-1) to assess the imaging window.
Patients then received either placebo or sildenaﬁl and
started to breathe through mask either room air or the hypoxic
gas mixture. The patient was blind to gas allocation. After
30 minutes, a second dose of sildenaﬁl or placebo was given
if the systolic arterial pressure did not decrease by .20 mm
Hg or to ,85 mm Hg. After 75 minutes of breathing air or
15% oxygen, a second, more complete, echocardiogram
(Echo-2) was performed and venous blood was sampled.
The patient then undertook low-level steady-state (25 W)
semirecumbent bicycle exercise (GE, Norway) with continu-
ous noninvasive monitoring of blood pressure and electrocar-
diogram. A further echocardiogram (Echo-3) was performed
after 5 minutes during exercise. Patients were then encour-
aged to exercise for as long as they believed able, and the
duration was recorded. The patients rested semirecumbent on
the bicycle, and the mask was taken away. After 5 minutes of
recovery, measurements were repeated (Echo-4). At the end
of exercise, patients were asked to rate the severity of breath-
lessness before and after exercise using a modiﬁed Borg
dyspnea scale.19
Echocardiographic Measurements
Echocardiograms were performed using a VIVID 9
machine (GE Healthcare, United Kingdom) and sets of
images recommended by the American Society of Echocar-
diography stored for ofﬂine analysis.20 Each measure was an
average of 3 consecutive cardiac cycles. Echo-1 was purely
performed for orientation. Echo-2 focused on LV and RV
systolic and diastolic function and measurements of PA pres-
sure. LV systolic function was assessed by tissue Doppler
imaging (TDI) with measurement of septal and lateral mitral
annular peak systolic acceleration and their mean (mean Sam).
Diastolic LV function was assessed by measuring early (Em)
and late (Am) transmitral ﬂow using pulsed Doppler and the
FIGURE 1. Study plan.
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mean of the early diastolic peak velocities of the lateral and
septal mitral annular using TDI; (mean Eam and mean Aam
waves). Left atria pressure was estimated using Em/mean Eam
ratio. RV systolic function was assessed using TDI by mea-
suring tricuspid annular peak velocities (Sat). RV diastolic
function was estimated from the ratio of early (Et) to late
(At) transtricuspid diastolic ﬂow and by the Et/Eat, where
Eat is the tricuspid annular early peak diastolic acceleration.
The RV systolic tricuspid gradient (RVTG) was calculated
and used as an estimate of systolic PA pressure. Patients with
RVTG .25 mm Hg were deﬁned as having pulmonary
hypertension (PH+). Echo-3 was performed during exercise
and included measurement of LV systolic and diastolic func-
tion, RV systolic function, and PA pressure estimation. Echo-
4 was performed to ensure the return of CO and RVTG to
baseline.
Statistics
To calculate the number of subjects required for the
study, we deﬁned a nominal primary outcome as the
difference between PA systolic pressure measured at baseline
(air rest) and at rest after breathing 15% oxygen for
75 minutes on placebo versus sildenaﬁl. Within patient,
repeated-measures of TR velocity over 1 hour have an SD
of 0.3 m/s in our laboratory. Given an expected mean baseline
TR velocity of 2.5 m/s (reﬂecting a PA pressure of
approximately 30 mm Hg) and an expected change in TR
velocity with hypoxia of 0.5 m/s, the study required 10
patients to show an effect of hypoxia, and assuming no
placebo response, a similar number to identify a response to
sildenaﬁl. Power was set at 90% and signiﬁcance at 5%
(2-tailed). Conservatively, and to study possible interactions
between baseline characteristics and interventions, we
decided to include 18 patients. Formal adjustments for
multiple comparisons were not made as the study was not
designed to show therapeutic beneﬁt but rather to explore
mechanisms and assess the utility of a noninvasive model for
the investigation of treatments for PH.21
Data are presented as mean and SD. The main
comparisons of interest were the difference between rest
TABLE 1. Baseline Characteristics of the Patients With CHF
Variables All (n = 18) PH2 (n = 11) PH+ (n = 7)
Clinical
Age, yr 64 6 8 62 6 6 69 6 9
Men, % 16 (89) 9 (82) 7 (100)
BMI, kg/m2 26 6 4 26 6 4 28 6 4
Ischemic heart disease, n (%) 14 (78) 8 (73) 6 (86)
CABG, n (%) 9 (50) 4 (36) 5 (71)
Epworth scale, score 7.3 6 4.0 7.1 6 4.3 7.6 6 3.8
SDB, n (%) 1 (6) 0 1 (14)
NYHA, class 2.2 6 0.7 2.0 6 0.8 2.6 6 0.5
6-min walk test, m 405 6 65 401 6 59 415 6 59
NT-pro-BNP, pg/mL 867 (548–2268) 668 (469–942) 2283 (1590–2630)
Electrocardiogram
HR, bpm 58 6 2 57 6 8 60 6 14
PR, ms 174 6 36 162 6 37 193 6 27
QRS, ms 126 6 33 129 6 38 123 6 27
Echocardiography
LVEDV, mL 147 6 67 142 6 51 156 6 90
LVEF, % 36 6 9 35 6 10 36 6 6
RVTG, mm Hg* 24 6 8 18 6 3† 33 6 5
RVEDA, cm2 19 6 9 15 6 8† 25 6 7
RVFA, % 48 6 8 42 6 8† 52 6 5
Treatment, %
b-blocker 17 (94) 11 (100) 6 (86)
ACEi 15 (83) 9 (82) 6 (86)
ARB 4 (22) 3 (27) 1 (14)
Loop diuretic 12 (67) 8 (73) 4 (57)
Spironolactone Ant 13 (72) 8 (73) 5 (71)
Statin 14 (78) 8 (73) 6 (86)
CRT 2 (11) 2 (18) 0
*RVTG value before starting the experiment the air-placebo day.
†The only variables with signiﬁcant difference between PH+ and PH2 were RVTG (by deﬁnition, P = 0.0001), RVFA (P = 0.007), and RVEDA (P = 0.016).
ACEi, angiotensin; BMI, body mass index; CABG, coronary artery bypass graft; LVEDV, left ventricular end diastolic volume; NYHA, New York Heart Association Dyspnea
Scale; RVEDA, right ventricle end diastolic area; RVF, right ventricular sign of congestion; RVFA, right ventricular fractionning ar; SDB, sleep apnea disorder.
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and exercise during the control period (breathing air and
dosing with placebo) at 75 minutes; the difference between
resting control measurements against the 3 interventions
(hypoxia, sildenaﬁl, and their combination) at 75 minutes;
and a comparison of the change from rest to maximal exercise
between control and the 3 interventions. In each case, paired
sample t tests were used to compare each set of interventions
against control. A P value #0.05 (2-tailed) was considered
signiﬁcant. This was an exploratory concept study, and there-
fore, no adjustment was made for multiple comparisons, and
differences other than TR velocity should be considered nom-
inal only.21
RESULTS
Noninvasive Human Model for the Study of
Secondary Pulmonary Hypertension
Twenty patients were consented, but 2 had insufﬁcient
tricuspid regurgitation to allow measurement of RVTG on the
ﬁrst study day and were excluded from the study. All patients
received 2 doses of placebo but the second dose of sildenaﬁl
was withheld in 2 patients who had an asymptomatic fall in
SBP by .20 mm Hg after the ﬁrst dose while breathing 15%
oxygen. Two other patients declined to exercise. All patients
otherwise completed the study without complications.
Baseline Characteristics
Most patients had ischemic heart disease, were in New
York Heart Association class II, and were on guideline-
indicated therapies (Tables 1 and 2). Baseline SaO2 was
.97% and LVEF ,50% in all patients. The mean (SD) LV
ejection fraction was 36 6 9%, and the median NT-pro-BNP
was 867 (interquartile range, 548–2268) pg/mL (Table 1).
Mean LV ﬁlling and PA pressures were increased and RV
systolic function reduced. No change in patients’ day-to-day
ratings of their breathlessness occurred during the course of
the study.
Control Period Compared With Baseline
Compared with baseline, at rest, while breathing air
75 minutes after the ﬁrst dose of placebo, there was no major
change in SaO2 (Fig. 2A), hemodynamic, or main echocar-
diographic variables (RVTG; Fig. 2B) (Table 3).
Hypoxia Versus Air at Rest
Compared with air, hypoxia caused a decrease in SaO2
(25.5 6 0.6%, P = 0.001) and an increase in RVTG (4.6 mm
Hg 6 4.0) (Fig. 2B and Table 4). Hemodynamic and echo-
cardiographic variables were otherwise similar while breath-
ing air or 15% oxygen (Table 4).
Sildenafil Versus Placebo at Rest
While breathing air, and compared with placebo,
sildenaﬁl caused a decrease in SaO2 (Fig. 2A and Table 4),
SVR, and RVTG (Fig. 2B and Table 4). Sildenaﬁl did not
exacerbate the decrease in SaO2 induced by hypoxia (Fig.
2A). Hypoxia did not attenuate the decrease in RVTG after
administering sildenaﬁl (Fig. 2B). The effects of sildenaﬁl in
the presence and absence of hypoxia were generally similar;
but in the presence of hypoxia, sildenaﬁl may have caused
more systemic vasodilation leading to a more pronounced
decrement in SBP and improvement in LV systolic function
as measured by Sam (Table 4).
Effects of Exercise
During exercise at 25 W, HR, blood pressure, CO, and
RVTG increased substantially, but SVR and SaO2 were sim-
ilar to resting measurements (Table 3).
TABLE 2. Patient-reported Symptoms at Rest and During Exercise in Daily Life and as Reported During Direct Observation on the
Day of Study
Variables Air-Placebo Hypoxia-Placebo Air-Sildenaﬁl Hypoxia-Sildenaﬁl
Breathlessness score during study
evaluation
At rest, 75 min after dosing
(n = 18)
0.19 6 0.49 0.18 6 0.50 0.19 6 0.71 0.08 6 0.26
During exercise at 25 W after
dosing (n = 16)*
2.38 6 2.33 2.91 6 2.76 1.38 6 1.78† 2.09 6 2.23
Exercise duration, s
All patients with exercise (n = 16) 628 6 291 533 6 261 621 6 258 584 6 254
PH2 (n = 11) 743 6 273 571 6 267‡ 704 6 261 675 6 237
PH+ (n = 5) 436 6 221§ 463 6 260§ 483 6 203§ 434 6 220§
Exercise stopped due to
breathlessness, n (%)
9 (56) 8 (50) 6 (38) 6 (38)
Values are expressed in mean 6 SD.
Breathlessness score was evaluated on each day before the study started and at rest 75 minutes after dosing and again at the end of exercise at 25 W.
*Patients were more breathless during exercise than at rest (P , 0.0001), but no between-group differences were observed. There was no signiﬁcant difference between PH+ and
PH2.
†P value for comparison between air-placebo and air-sildenaﬁl during the exercise: P = 0.088.
‡P , 0.05 versus air placebo day in the same group (all or PH2 or PH+).
§P , 0.05 PH + versus PH2 same intervention (air-placebo, hypoxia-placebo, sildenaﬁl-placebo, or hypoxia-placebo).
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Effects of Hypoxia During Exercise
The duration of exercise was slightly shorter when
breathing 15% oxygen, an effect that was nominally
signiﬁcant in the subgroup that did not have PH (Table 2).
SaO2 was slightly but not signiﬁcantly lower during exercise
at 25 W when breathing 15% oxygen rather than room air.
Few differences were observed apart from an increase in Sat
suggesting a greater increase in RV systolic contraction
(Table 5). Hypoxia had little if any effect on the rise in
RVTG during exercise.
Sildenafil Compared With Placebo During
Exercise
Sildenaﬁl did not substantially reduce the rise in RVTG
with exercise nor cause a decrease in SaO2 during exercise at
25 W when breathing air. Comparing exercise after placebo
while breathing air to exercise after sildenaﬁl while breathing
15% oxygen, SaO2 and SVR were lower and CO and RV
systolic performance (Sat) were increased but the increase in
RVTG was not attenuated (Table 5). Sildenaﬁl prevented the
decline in exercise duration associated with hypoxia in pa-
tients who did not have PH (Table 2).
Comparison of Patients With or Without PH
Patients with PH, deﬁned as RVTG .25 mm Hg
(n = 7), had a more marked decrease in SaO2 and increase
in RVTG at rest in response to hypoxia (Figs. 3A–D) and
greater fall in SVR and increase in Sat with sildenaﬁl
(data not shown).
Breathing air, patients with PH had a markedly shorter
exercise duration compared with those without PH (Table 2),
which was not modiﬁed by any intervention. In contrast,
FIGURE 2. Change in SaO2 (A) and in RVTG
(B) with hypoxia and sildenafil alone and in
combination in all patients. Black circle: air
placebo, open circle: air sildenafil; black
square: hypoxia placebo; open square:
hypoxia sildenafil. *P # 0.05 versus AP.
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patients without PH exercised for a shorter time during hyp-
oxia than air, an effect that was reversed by sildenaﬁl
(Table 2). The hemodynamic effects of sildenaﬁl during hyp-
oxia and exercise, including reductions in SVR and increases
in CO and Sat, were more marked in those without PH (data
not shown).
DISCUSSION
This study emphasizes the complex pathophysiology of
pulmonary hemodynamic in patients with CHF. Four major
components can be assessed in our model: left atrial pressure,
ﬁxed and variable components to pulmonary vascular resis-
tance, and ventilation–perfusion matching. Changes in left
atrial pressure can be assessed by E/Ea, the ﬁxed component
of pulmonary vascular resistance by the change in RVTG in
response to an increase in exercise-induced CO, the variable
component of pulmonary vascular resistance by the change in
RVTG in response to hypoxia and ventilation–perfusion
matching by changes in SaO2 while breathing air that may
be exacerbated by breathing 15% oxygen. The study shows
that sildenaﬁl reduces pulmonary pressure but has limited
effects on left atrial pressure and on the pulmonary circulation
due to what appears to be a large ﬁxed component to pulmo-
nary vascular resistance. Moreover, pulmonary vasodilation is
relatively unselective leading to shunting of blood through
poorly ventilated lung regions leading, in turn, to a decrease
in SaO2. Sildenaﬁl did cause a decline in PA pressure at rest
and completely abolished hypoxia-induced pulmonary vaso-
constriction but did not substantially reduce the increase in
PA pressure during exercise-induced increases in CO;
although because CO was somewhat higher while exercising
after taking sildenaﬁl, pulmonary vascular resistance might
have been slightly reduced. Measurements of RV function
improved after sildenaﬁl both at rest and during exercise con-
sistent with a reduction in RV afterload or, less likely, a pos-
itive inotropic effect.22 Overall, these data suggest
a substantial relatively ﬁxed component to PH in patients with
CHF. The more favorable effects of sildenaﬁl on hemody-
namics during exercise among patients with lower PA pres-
sure, who may have a smaller ﬁxed component to pulmonary
vascular resistance, are consistent with this concept. How-
ever, it is possible that longer term treatment with an agent
such as sildenaﬁl could cause favorable remodeling of the
pulmonary vasculature leading to a reduction in this relatively
ﬁxed component.
The pulmonary circulation responds to acute hypoxia
with arteriolar vasoconstriction and a rise in pulmonary artery
pressure.6–8 In normal subjects,8,23 hypoxia causes arterial
oxygen desaturation, increases in pulmonary artery pressure,
HR, myocardial contractility, and CO but with no obvious
effect on RV function.23 Little is known about systemic and
cardiovascular interactions induced by hypoxia in patients
with CHF. Nevertheless, acute hypoxia might be frequent in
patient with CHF, occurring, for example, during sleep apnea,
acute heart failure, or ﬂight travel.24
We have recently reported25 that 60 minutes of 15%
oxygen at rest caused an increase in systolic PA pressure to
a similar level in patients with heart failure and normal sub-
jects.25 We found a similar increase in PA pressure after
75 minutes in this study and conﬁrmed that short-term mod-
erate hypoxemia had little effect on LV and RV systolic
function in this population.25
Sildenaﬁl blunted the hypoxia-induced increase in
pulmonary artery systolic pressure at rest in patients with
CHF. Similar effects have been shown in healthy volunteers
in whom sildenaﬁl inhibits the development of PH in
response to acute hypoxia at high altitude.26 Phosphodiester-
ase 5 inhibition is a relatively new strategy for the treatment
of PH27 and RV dysfunction,22,28 causing both pulmonary
vasodilatation and regression of pulmonary arteriolar muscu-
lar hypertrophy.29,30 Phosphodiesterase 5 is the major enzyme
responsible for degrading cyclic guanosine monophosphate in
vascular smooth cells of the lung.31 It is increased in the lung
tissue of patients with PH and may contribute to decreased
NO-dependent vasodilatation.29
Previous studies in patients with CHF due to LV
systolic dysfunction suggest that sildenaﬁl acutely reduces
PA pressures, measured by catheter, both at rest and during
exercise (upright bicycle), and improves peak oxygen con-
sumption (VO2) and right heart hemodynamics, particularly
TABLE 3. Absolute Values at Rest (75 Minutes) and During
Exercise at 25 W for the Air-Placebo Group
Air Placebo Variables Rest (75 min) Exercise P
Saturation
SaO2, % 97.7 6 1.4 97.4 6 1.2 0.50
Hemodynamic
SBP, mm Hg 114 6 13 161 6 21 0.0001
DBP, mm Hg 59 6 6 88 6 12 0.0001
SVR, dyn$s21$cm22 1357 6 264 1503 6 483 0.14
HR, bpm 57 6 7 90 6 13 0.0001
SV, mL 86 6 13 76 6 16 0.023
CO, L/min 4.8 6 0.7 6.9 6 2.0 0.001
LV
Mean Sam, cm/s 5.1 6 1.2 5.9 6 1.4 0.019
Mean Eam, cm/s 5.5 6 1.7 7.3 6 2.8 0.013
Em, cm/s 71 6 30 88 6 21 0.027
Am, cm/s 51 6 20 65 6 29 0.045
Em/Am 1.7 6 1.2 1.8 6 1.2 0.79
Em/mean Ea 15.0 6 9.1 14.0 6 6.9 0.79
Pulmonary pressure
RVTG, mm Hg 23.6 6 8.7 43.1 6 16.7 0.0001
RV
Sat, cm/s 10.1 6 3.1 10.2 6 3.6 0.73
Eat, cm/s 7.3 6 2.3 — —
Et, cm/s 45 6 11 — —
Et/At 1.3 6 0.4 — —
Et/Eat 6.7 6 2.7 — —
CO, cardiac output; DBP, diastolic blood pressure; Em and Am, early and late
diastolic peak velocities of the transmitral ﬂow measured in pulsed Doppler; Et, early
diastolic velocities of the transtricupid ﬂow measured in pulsed wave Doppler; Mean
Eam, mean of the early diastolic peak velocities of the LV lateral and septal wall in tissue
Doppler; Mean Sam, mean of the peak systolic velocities of the LV lateral and septal
wall in tissue Doppler; SaO2, oxygen saturation; Sat and Eat, peak systolic velocity and
early diastolic velocity of the tricuspid annulus measured in tissue Doppler; SBP, sys-
tolic blood pressure; SV, LV stroke volume; SVR, systemic vascular resistance.
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in patients with PH.28 In this last study, the mean PA pressure
was reduced by sildenaﬁl administered open-label from
28 6 4 mm Hg by 14 6 5% at rest and from 36 6 5 mm
Hg by 11 6 3% during exercise. In our study, sildenaﬁl did
not appear to reduce PA pressure during exercise substantially
and did not improve breathlessness or exercise duration,
except in a subgroup analysis of patients who did not have
PH when breathing 15% oxygen. The reasons for these differ-
ences are not obvious but could reﬂect blinding, different
types of exercise, posture, and protocol (6.25–12.5 W/min
incremental ramp protocol) and whether exercise was con-
ducted after an overnight fast. In contrast, long-term use of
sildenaﬁl did not improve symptoms, exercise capacity, or
outcome in a recent substantial trial of patients with heart
failure and preserved LVEF.32
In contrast to Guazzi et al,33 we found that sildenaﬁl
reduced SaO2 in patients with CHF. Interestingly, in an
experimental model using anesthetized normal pigs,
Kleinsasser et al34 also reported that sildenaﬁl administra-
tion reduced SaO2 due to an increase in intrapulmonary
shunt ﬂow. In a clinical study in patients with LV dysfunc-
tion and PH, Matamis et al35 also reported that sildenaﬁl
increased ventilation–perfusion mismatch resulting in
reduction in SaO2. These data suggest that sildenaﬁl ex-
acerbates ventilation–perfusion mismatch due to vasodila-
tion of poorly ventilated lung regions. Whether ventilation–
perfusion mismatch persists and, if so, its long-term conse-
quence are unknown. Sildenaﬁl had little effect on SaO2 during
exercise suggesting that ventilation–perfusion matching may
improve during exercise. Interestingly, similar decreases in
SaO2 have been noted with endothelin antagonists in patients
with CHF.36 Although these agents may be useful for the man-
agement of PH, they have tended to have deleterious effects in
patients with CHF.36
LIMITATIONS
This was a relatively small study but we used a double-
blind crossover trial methodology, which avoids the variability
created by interindividual comparison and greatly enhances the
power to show differences. Most of the patients included in this
study were on b-blockers, which may have inhibited the sym-
pathetic activation induced by hypoxia, but it is more relevant
to the clinical situation to study patients while they are taking
TABLE 4. Echocardiography, Oxygen Saturations, and NonInvasive Hemodynamics at Rest 75 Minutes After Dosing
Variables
Changes Versus Air-Placebo at
Rest (Between Days)
Comparison With
Air-Placebo, P
Hypoxia-Placebo Air-Sildenaﬁl Hypoxia-Sildenaﬁl Hypoxia-Placebo Air-Sildenaﬁl Hypoxia-Sildenaﬁl
Saturation
SaO2, % 25.5 6 0.6 20.8 6 1.6 25.4 6 2.4 0.001 0.043 0.0001
Hemodynamic
SBP, mm Hg +3.3 6 11.4 23.7 6 9.1 25.1 6 10.3* 0.24 0.11 0.05
DBP, mm Hg +1.1 6 6.9 21.7 6 4.8 21.8 6 5.2 0.45 0.15 0.17
SVR, dyn$s21$cm22 230 6 172 287 6 156 2132 6 184 0.48 0.034 0.009
HR, bpm +1.4 6 5.8 +1.7 6 5.7 +2.5 6 5.7 0.30 0.22 0.08
SV, mL +0.75 6 8.2 20.35 6 7.12 +0.35 6 6.2 0.72 0.84 0.82
CO, L/min +0.28 6 0.71 +0.19 6 0.64 +0.28 6 0.66 0.12 0.25 0.10
LV
Mean Sam, cm/s 20.07 6 0.65 +0.44 6 1.33 +0.72 6 0.86 0.69 0.19 0.003
Mean Eam, cm/s 0 6 0.88 +0.40 6 1.39 +0.42 6 1.21 1.00 0.25 0.17
Em, cm/s 23.5 6 16.5 +0.2 6 17.0 25.2 6 4.0 0.40 0.96 0.21
Am, cm/s +5.4 6 18.5 +7.2 6 18.5 +4.8 6 19.4 0.25 0.13 0.33
Em/Am 20.14 6 1.11 20.13 6 1.12 20.17 6 1.08 0.63 0.65 0.54
Em/mean Eam 21.7 6 7.5 21.7 6 8.7 23.6 6 8.3 0.36 0.44 0.09
Pulmonary pressure
RVTG, mm Hg +4.6 6 4.0 22.2 6 4.6 22.1 6 4.3 0.001 0.05 0.05
RV
Sat, cm/s +0.5 6 1.2 +0.6 6 1.3 +0.3 6 1.6 0.07 0.09 0.40
Eat, cm/s (cm$s21) +1.1 6 1.3 +0.7 6 1.9 +0.4 6 1.7 0.002 0.16 0.36
Et, cm/s 21.4 6 2.7 21.5 6 10.8 +2.9 6 10.6 0.62 0.58 0.30
Et/At 20.15 6 0.28 20.13 6 0.27 20.15 6 0.40 0.05 0.07 0.17
Et/Eat 21.07 6 1.8 20.6 6 2.7 +0.09 6 3.00 0.024 0.40 0.91
*Two patients did not receive the second dosage of sildenaﬁl due to a drop of systolic blood pressure .20 mm Hg.
CO, cardiac output; DBP, diastolic blood pressure; Em and Am, early and late diastolic peak velocities of the transmitral ﬂow measured in pulsed Doppler; Et, early diastolic
velocities of the transtricupid ﬂow measured in pulsed wave Doppler; Mean Eam, mean of the early diastolic peak velocities of the LV lateral and septal wall in tissue Doppler; Mean
Sam, mean of the peak systolic velocities of the LV lateral and septal wall in tissue Doppler; SaO2, oxygen saturation; Sat and Eat, peak systolic velocity and early diastolic velocity of
the tricuspid annulus measured in tissue Doppler; SBP, systolic blood pressure; SV, LV stroke volume; SVR, systemic vascular resistance.
Bold indicates statistical difference of P , 0.05.
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guideline-indicated therapies. We did not measure metabolic
gas exchange. We were not able to perform 2D strain mea-
surement because only 14 patients had sufﬁciently good
echocardiographic images at rest with fewer than that during
exercise. Measurement of pulmonary vascular resistance to
estimate change induced by hypoxia, exercise, and sildenaﬁl
TABLE 5. Echocardiography, Oxygen Saturations, and Noninvasive Hemodynamics During 25 W Bicycle Exercise 75 Minutes After
Dosing
Variables Changes Between Rest and Exercise for Each Group (During Each Day)
Breathing Treatment Air-Placebo Hypoxia-Placebo Air-Sildenaﬁl Hypoxia-Sildenaﬁl
Saturation
SaO2, % 20.3 6 1.4 22.5 6 3.7 20.8 6 1.5 22.6 6 3.1
Hemodynamic
SBP, mm Hg +48 6 15 +48 6 18 +46 6 19 +50 6 15
DBP, mm Hg +29 6 11 +28 6 12 +25 6 11 +28 6 24
SVR, dyn$s21$cm22 +145 6 348 +53 6 289 +72 6 510 247 6 171
HR, bpm +33 6 15 +31 6 17 +28 6 12 +31 6 14
SV, mL 29.7 6 14.1 25.6 6 12.6 20.7 6 15.0 +2.0 6 17.1
CO, L/min +2.1 6 1.8 +2.0 6 1.4 +2.2 6 1.7 +2.9 6 1.3
LV
Mean Sam, cm/s +0.80 6 1.16 +1.03 6 1.00 +1.43 6 1.09 +1.32 6 1.34
Mean Eam, cm/s +1.84 6 2.49 +2.90 6 3.51 +2.06 6 2.58 +2.76 6 2.86
Em, cm/s +17 6 28 +17 6 26 +25 6 21 +21 6 26
Am, cm/s +14.3 6 26.0 +12.5 6 26 +9.9 6 24.8 +14.4 6 26.9
Em/Am +0.11 6 1.6 +0.33 6 1.17 +0.08 6 0.28 +0.10 6 0.86
Em/mean Eam 20.51 6 7.21 20.80 6 4.67 20.51 6 6.30 20.33 6 3.91
Pulmonary pressure
RVTG, mm Hg +19.2 6 11.3 +23.3 6 10.4 +15.7 6 8.5 +19.7 6 10.1
RV
Sat, cm/s +0.11 6 1.21 +1.29 6 1.94 +1.36 6 1.78 +1.62 6 2.33
Variables Comparison for Each Group Between Rest and Exercise (P) Effect of Intervention on Exercise Response (P)
Breathing Treatment
Air-
Placebo
Hypoxia-
Placebo
Air-
Sildenaﬁl
Hypoxia-
Sildenaﬁl
Hypoxia-
Placebo
Air-
Sildenaﬁl
Hypoxia-
Sildenaﬁl
Saturation
SaO2, % 0.50 0.014 0.06 0.004 0.06 0.34 0.02
Hemodynamic
SBP, mm Hg 0.0001 0.0001 0.0001 0.0001 0.54 0.83 0.61
DBP, mm Hg 0.0001 0.0001 0.0001 0.0001 0.92 0.19 0.85
SVR, dyn$s21$cm22 0.14 0.47 0.59 0.32 0.24 0.63 0.031
HR, bpm 0.0001 0.0001 0.0001 0.0001 0.90 0.15 0.57
SV, mL 0.023 0.11 0.85 0.70 0.52 0.049 0.005
CO, L/min 0.001 0.0001 0.0001 0.0001 0.59 0.60 0.028
LV
Mean Sam, cm/s 0.019 0.002 0.0001 0.003 0.47 0.18 0.15
Mean Eam, cm/s 0.013 0.009 0.011 0.003 0.26 0.67 0.26
Em, cm/s 0.027 0.023 0.0001 0.007 0.90 0.38 0.74
Am, cm/s 0.045 0.085 0.15 0.066 0.82 0.36 0.91
Em/Am 0.79 0.43 0.47 0.71 0.66 0.45 0.67
Em/mean Eam 0.78 0.53 0.77 0.76 0.80 0.84 0.95
Pulmonary pressure
RVTG, mm Hg 0.0001 0.0001 0.0001 0.0001 0.18 0.12 0.88
RV
Sat, cm/s 0.73 0.018 0.008 0.014 0.023 0.007 0.011
CO, cardiac output; DBP, diastolic blood pressure; Em and Am, early and late diastolic peak velocities of the transmitral ﬂow measured in pulsed Doppler; Et,
early diastolic velocities of the transtricupid ﬂow measured in pulsed wave Doppler; Mean Eam, mean of the early diastolic peak velocities of the LV lateral and septal
wall in tissue Doppler; Mean Sam, mean of the peak systolic velocities of the LV lateral and septal wall in tissue Doppler; SaO2, oxygen saturation; Sat and Eat, peak
systolic velocity and early diastolic velocity of the tricuspid annulus measured in tissue Doppler; SBP, systolic blood pressure; SV, LV stroke volume; SVR, systemic vascular
resistance.
Bold indicates statistical difference of P , 0.05.
Damy et al J Cardiovasc Pharmacol  Volume 66, Number 3, September 2015
236 | www.jcvp.org Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
Copyright © 201 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.5
would have been interesting in this model. However, non-
invasive estimation of PVR by echocardiography is still chal-
lenging and with limited agreement with invasive
measurement.37,38 Because of the limited number of patients
included in our study, estimation of PVR by echocardiogra-
phy was not reliable.
CONCLUSIONS
A dynamic noninvasive model may prove useful for
assessing the effects of intervention on pulmonary hemody-
namic in patients with CHF. Exercise-induced increases in
CO are associated with a marked increase in PA pressure
indicating a failure of normal physiological pulmonary
vasodilation. The effects of sildenaﬁl on pulmonary hemo-
dynamics are complex and not entirely favorable. Sildenaﬁl
increased ventilation–perfusion mismatching at rest and
failed to increase pulmonary vasodilation during exercise
substantially.
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